Edition:
India

People: Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

7.33USD
20 Sep 2019
Change (% chg)

$0.58 (+8.59%)
Prev Close
$6.75
Open
$6.74
Day's High
$7.41
Day's Low
$6.74
Volume
432,168
Avg. Vol
108,554
52-wk High
$20.63
52-wk Low
$4.21

Merriweather, Alfred 

Mr. Alfred G. Merriweather is no longer as Chief Financial Officer of the company. Effective October 31, 2019. Mr. Merriweather has held executive leadership roles at numerous companies in the life sciences industry throughout his career. Before coming to Adamas, he was Chief Financial Officer at RainDance Technologies, Inc., a life science tools company, from November 2013 to February 2017, where he was responsible for the finance, information technology, human resources and general legal functions. Prior to RainDance, he served as Chief Financial Officer of Verinata Health, Inc., a prenatal laboratory testing company, from January 2012 to July 2013, where he was responsible for the finance and general legal functions, and as Senior Vice President and Chief Financial Officer of Celera Corporation, a diagnostic products and laboratory testing company, from December 2010 until May 2011, where he was responsible for the finance and information technology functions. Mr. Merriweather has spent over 25 years in senior financial positions at several private and public life science companies, including Monogram Biosciences, Inc. and Laserscope. Mr. Merriweather received a Bachelor’s degree from the University of Cambridge in the United Kingdom.

Basic Compensation

Total Annual Compensation, USD 600,600
Restricted Stock Award, USD 214,903
Long-Term Incentive Plans, USD --
All Other, USD 821,547
Fiscal Year Total, USD 1,637,050

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --